Collapsing glomerulopathy (CG) has become an important cause of ESRD. First delineated
from other proteinuric glomerular lesions in the 1980s, CG is now recognized as a common,
distinct pattern of proliferative parenchymal injury that portends a rapid loss of renal function
and poor responses to empiric therapy. Notwithstanding, the rise in disorders that are
associated with CG, the identification of the first susceptibility genes for CG, the remarkable
increase in murine modeling of CG, and promising preclinical testing of new therapeutic …